Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03968211 · ClinicalTrials.gov registry record · Phase 1
Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency
A Phase 1 study, sponsored by University of Virginia.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT03968211 is a Phase 1 study that has completed, run by University of Virginia. The registered enrollment target is 37 participants.
The verdict
NCT03968211, a Phase 1 study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
This study is trying to find out if an undetectable serum immunoglobulin E (IgE) is a biomarker, or early sign of, the development of immune deficiency.
Interventions
- BIOLOGICAL Salmonella typhi polysaccharide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2023-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03968211
The ClinicalTrials.gov registry entry for NCT03968211 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Salmonella typhi polysaccharide vaccine is the first listed.
NCT03968211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03968211 about?
NCT03968211 is a clinical study titled "Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency". This study is trying to find out if an undetectable serum immunoglobulin E (IgE) is a biomarker, or early sign of, the development of immune deficiency.
What is the current status of trial NCT03968211?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2019-07-01. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT03968211?
The interventions under investigation include: Salmonella typhi polysaccharide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03968211?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.